Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors

Hepatology

Volumn 56, Issue 5, 2012, Pages 1817-1827

  Neumann, Olaf ^a   Kesselmeier, Miriam ^a   Geffers, Robert ^b   Pellegrino, Rossella ^a   Radlwimmer, Bernhard ^c   Hoffmann, Katrin ^a   Ehemann, Volker ^a   Schemmer, Peter ^a   Schirmacher, Peter ^a   Lorenzo Bermejo, Justo ^a   Longerich, Thomas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; FATTY ACID BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; GENE DOSAGE; GENE IDENTIFICATION; GENE SILENCING; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOME IMPRINTING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD PROTEINS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLYCOPROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERIOD CIRCADIAN PROTEINS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84868201629     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25870     Document Type: Article

References (50)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
2. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000; 76: 4-11.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
4. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
5. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001; 293: 1089-1093.
6. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467: 285-290.
7. Gonzales KA, Ng HH. Choreographing pluripotency and cell fate with transcription factors. Biochim Biophys Acta 2011; 1809: 337-349.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
9. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, et al. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. HEPATOLOGY 2002; 36: 427-432.
10. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. HEPATOLOGY 2008; 47: 908-918.
11. Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. HEPATOLOGY 2008; 47: 511-520.
12. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
13. Longerich T, Breuhahn K, Odenthal M, Petmecky K, Schirmacher P. Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma. Virchows Arch 2004; 445: 589-596.
14. Brauckhoff A, Malz M, Tschaharganeh D, Malek N, Weber A, Riener MO, et al. Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells. J Hepatol 2011; 55: 1049-1057.
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
16. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232-236.
17. Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010; 88: 287-292.
18. Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS. Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 2011; 54: 311-319.
19. Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, Martinez N, Varela M, Luka Z, et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. HEPATOLOGY 2008; 47: 1191-1199.
20. Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008; 29: 1901-1910.
21. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 2010; 5: e9749.
22. Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 2012; 130: 1319-1328.
23. Tao R, Li J, Xin J, Wu J, Guo J, Zhang L, et al. Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 2011; 6: e19862.
24. Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. HEPATOLOGY 2012; 55: 1799-1808.
25. Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, et al. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 2003; 201: 250-259.
26. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-1773.
27. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. HEPATOLOGY 2007; 45: 42-52.
28. Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR. Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res 2007; 67: 4586-4594.
29. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
30. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111: 197-208.
31. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441: 349-353.
32. Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005; 24: 117-125.
33. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007; 39: 157-158.
34. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-1063.
35. Lu CY, Hsieh SY, Lu YJ, Wu CS, Chen LC, Lo SJ, et al. Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosomes Cancer 2009; 48: 1057-1068.
36. Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, et al. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol 2011; 18: 572-579.
37. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG, Szyf M. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 2011; 71: 5891-5903.
38. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog 2008; 47: 925-933.
39. McHugh PP, Gilbert J, Vera S, Koch A, Ranjan D, Gedaly R. Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma. HPB (Oxford) 2010; 12: 56-61.
40. Longerich T, Mueller MM, Breuhahn K, Schirmacher P, Benner A, Heiss C. Oncogenetic tree modeling of human hepatocarcinogenesis. Int J Cancer 2012; 130: 575-583.
41. Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, Sakaki Y. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 1997; 389: 512-516.
42. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006; 15 Spec No 2: R271-R277.
43. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2, and PER3 genes in breast cancers. Carcinogenesis 2005; 26: 1241-1246.
44. Hunt T, Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell 2007; 129: 461-464.
45. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006; 22: 375-382.
46. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 2010; 28: 3770-3778.
47. Im JS, Jung BH, Kim SE, Lee KH, Lee JK. Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett 2010; 584: 4731-4734.
48. Domene HM, Hwa V, Argente J, Wit JM, Camacho-Hubner C, Jasper HG, et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009; 72: 129-141.
49. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800.
50. Vasse M. The protein Z/protein Z-dependent protease inhibitor complex. Systemic or local control of coagulation? Hamostaseologie 2011; 31: 155-158, 160-164.